Navigation Links
Questcor Reports Third Quarter Financial Results
Date:10/29/2013

nical studies. Questcor is funding research and development, both in-house and through independent physician sponsored studies, for the following:

Label Enhancement Programs:

  • Acute Respiratory Distress Syndrome (ARDS): The Company announced on October 22, 2013 that it will commence a Phase 2 study to explore the efficacy and safety of Acthar in patients with ARDS. ARDS is an acute life threatening lung condition that can result from pulmonary and non-pulmonary infections or a multitude of other serious conditions.
  • Amyotrophic Lateral Sclerosis (ALS): Patient recruitment continues at thirteen U.S. clinical sites in a company-sponsored dose-ranging Phase 2 clinical trial to evaluate the safety and tolerability of Acthar in patients with ALS, often referred to as Lou Gehrig's disease. ALS is a life-threatening, progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord.
  • Diabetic Nephropathy: Enrollment continues in a company-sponsored Phase 2 trial to evaluate the efficacy and safety of Acthar in patients with diabetic nephropathy, one of the most common causes of end-stage renal disease in the United States.
  • Research Regarding Approved Indications:

  • Idiopathic Membranous Nephropathy: Enrollment continues in a company-sponsored Phase 4 trial in idiopathic membranous nephropathy. Patients enrolled in this study are refractory, or non-responsive, to current standard therapies or have relapsed after partial remission on current standard therapies.
  • Lupus: Enrollment continues in a company-sponsored multi-site Phase 4 company-sponsored clinical trial to evaluate the efficacy and safety of daily Acthar administration over a 6-month period in patients with persistently active lupus.
  • Planning activities related to the initial evaluation of a select grouping of potential Synacthen indications are in progress.  Questcor will provide further updates on this development
    '/>"/>

    SOURCE Questcor Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

    Related medicine technology :

    1. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
    2. Questcor to Report Second Quarter Results on July 24, 2012
    3. Questcor Reports Second Quarter Financial Results
    4. Questcor Pharmaceuticals to Present at Investor Conferences in September
    5. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
    6. Questcor Comments on Insurance Policy Bulletin
    7. Questcor to Conduct Conference Call to Discuss Reimbursement Process
    8. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
    9. Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
    10. Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development
    11. Questcor to Report Fourth Quarter and Full Year 2012 Financial Results on February 26, 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/24/2014)... 2014  Medical Science Liaisons play a large role ... the medical device industry and key stakeholders, the role ... years as the device industry relies on them to ... by benchmarking firm, Best Practices, LLC, one area where ... is by harnessing new technology to enable education. Online ...
    (Date:12/22/2014)... 2014   TRU-D SmartUVC LLC, producers of ... announced today that the General Services Administration has awarded ...   This newly formed agreement will allow ... government purchasers, including Department of Veteran Affairs and Department ... contacts purchasing solutions for the Ebola effort in ...
    (Date:12/22/2014)... Dec. 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: ... on discovering, developing and commercializing innovative therapies addressing ... issued the following open letter to shareholders from ... Med. Sc. Dear RXi Shareholders, ... of inaccurate statements posted on certain social media ...
    Breaking Medicine Technology:Role of Medical Science Liaisons Evolving in Medical Device Sector 2TRU-D SmartUVC LLC Awarded General Services Administration Contract to Expand Government Customer Base 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6
    ... FRANCISCO, Calif., Jan. 17, 2012  Onyx Pharmaceuticals, Inc. ... from the Bayer HealthCare Phase 3 CORRECT (Colorectal ... of standard therapy) trial of Bayer,s investigational compound ... endpoint, showing statistically significant improvement in overall survival ...
    ... today visited the future site of Endo Pharmaceutical,s corporate headquarters ... continued commitment to the region and its plans to create ... Pennsylvania we are employing the kind of creative cooperation that ... ribbon on a new headquarters," said Corbett. "This investment in ...
    Cached Medicine Technology:Phase 3 Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi 2Phase 3 Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi 3Phase 3 Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi 4Phase 3 Data Show Bayer's Investigational Compound Regorafenib (BAY 73-4506) Met Primary Endpoint Showing Statistically Significant Improvement in Overall Survival in Patients with Metastatic Colorectal Cancer Refractory to Standard Approved Therapi 5
    (Date:12/25/2014)... Dennis Thompson HealthDay Reporter ... be closing in on a "fountain of youth" drug that ... of older adults, a new study suggests. Seniors received ... drug that targets a genetic signaling pathway linked to aging ... The experimental medication, a version of the ...
    (Date:12/25/2014)... December 25, 2014 Plugin creators from ... 5k. A fully customizable business presentation tool made specifically ... the ProFire 5k business tool, users can now display ... CEO of Pixel Film Studios. “ProFire 5k gives users ... to add professionalism to a presentation” , Pixel Film ...
    (Date:12/24/2014)... Wauwatosa, Wi (PRWEB) December 25, 2014 ... who are unable to afford certain items. During the holiday ... , "We collected over 70 toys," says Dr. Sara Mahalko-Leonhardt, ... myself and staff such joy, knowing that we are able ... any present had it not been for the generosity of ...
    (Date:12/24/2014)... Recently, iFitDress.com, a famous dress manufacturer and ... under $150 . All these items are brand new; they ... already been updated with the new range of high quality ... far. All iFitDress.com’s designs are made according to the latest ... materials. Every outfit from the company is handpicked by skilled ...
    (Date:12/24/2014)... York (PRWEB) December 24, 2014 ... ) that allege the blood thinner caused life-threatening ... outlined a leadership structure for the proceeding, Bernstein ... December 17th, the Court plans to select lawyers ... and also plans on appointing a Plaintiffs’ Steering ...
    Breaking Medicine News(10 mins):Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 2Health News:Researchers Take 'First Baby Step' Toward Anti-Aging Drug 3Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:AlignLife of Wauwatosa Brings Joy to Less Fortunate Families 2Health News:Many Prom Dresses under 150 from Well-known Dress Manufacturer iFitDress.com 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3
    ... promises, claimed patients in a survey despite the government promises ... patients survey has found high levels of general satisfaction with ... of the 80,000 people who took part a different picture ... ‘very clean’ as compared to 56% in 2002. While at ...
    ... the NHS staff should be praised for their efforts and ... the "best ever". He said that the maximum waiting time ... ,Reports indicated that the figures up to 31st ... with an 18-week wait for treatment was at its lowest ...
    ... in Ranchi, the Jharkhand Health department today said the ... // ,'We have equipped the Sadar hospital ... patients,' Health and Family Welfare's joint secretary R C ... free treatment at the hospital instead of streaming to ...
    ... world , including India, must face the challenges of ... their citizens get access to effective healthcare // , ... medical expenses, a new World Bank report said. ... to cope with sharply rising costs even while countries ...
    ... of the anti-quota strike call given by the Indian ... (BMC) // and Government Dental colleges today struck ... services in Victoria and Vani Vilas and government dental ... affected, Dr Venugopal, President, Junior Doctors Assoication, BMC told ...
    ... 25 (pti) As part of Tsunami relief efforts ... inaugurated at Thennampattinam, a tsunami-hit village in Sirkali ... Wucherer,member, corporate executive committee of Siemens, AG declared ... community and Consulate General, Earthquake assistant foundation through ...
    Cached Medicine News:Health News:Quality Of NHS Hospitals Getting Dirtier Despite Promises 2Health News:Health Minister Praises Efforts By NHS In Reducing Patient Waiting Time 2Health News:Health Minister Praises Efforts By NHS In Reducing Patient Waiting Time 3
    7 mm strong curved blade. Round handle....
    3 mm diameter roller blade in line with handle. Curved shaft. Flat handle. 15 mm from curve to tip....
    5 mm diameter blade. Angled 45 degrees. Hexagonal handle....
    0.5 mm wide x 1.5 mm long. Angled 20 degrees. Octagonal handle....
    Medicine Products: